Algeta ASA, a therapeutics company dedicated to the development of novel anticancer agents based on alpha-particle emitting radionuclides, is pleased to announce the publication of its study demonstrating the potential of monoclonal antibodies (mAbs) labeled with alpha-emitting radionuclides for the targeting and treatment of cancer. Through the application of Algeta’s proprietary TH-1 Therapeutic Antibody Enhancement technology, it has been shown that in vivo a Thorium-227 conjugate of the chimeric mAb rituximab retains immunoreactivity against human CD20-positive cells and its biodistribution properties are compatible with therapeutic mAbs developed for oncology indications.
